MetaVia Unveils New Research on DA-1726
MetaVia Inc. (NASDAQ: MTVA), a leading clinical-stage biotechnology company dedicated to addressing cardiometabolic diseases, has exciting news regarding its investigational therapy DA-1726. This novel dual agonist, designed to target glucagon-like peptide-1 receptors (GLP1R) and glucagon receptors (GCGR), is making waves ahead of its poster presentations.
Poster Presentations at ObesityWeek 2025
Recently, the company announced two significant abstracts that have been selected for poster presentations at the highly anticipated ObesityWeek 2025. This event, which is set to take place both in-person and virtually, will gather experts and stakeholders in the field of obesity research.
Details of the Presentations
The first poster focuses on the safety, tolerability, and pharmacokinetics of DA-1726, offering insights from a Phase 1 study. Notably, the presenting author, Chris Fang, M.D., who serves as the Consulting Chief Medical Officer of MetaVia, will share findings that highlight the benefits of this innovative therapy. The session will occur on November 4, 2025, from 7:30 to 8:30 PM, in Exhibit Hall A1, under the poster number P-209.
In addition, another presentation will explore DA-1726's potential as a promising treatment for obesity and associated metabolic disorders. Tae-Hyoung Kim, M.S., the Lead Research Scientist of Dong-A ST, will present this work. This session will take place simultaneously with the first, also on November 4, 2025, at the same location, classified under poster number P-154.
About DA-1726
DA-1726 represents a breakthrough in the treatment of obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). This therapy operates as a dual oxyntomodulin (OXM) analogue, administered via subcutaneous injection on a weekly basis. DA-1726 functions effectively to suppress appetite and boost energy expenditure, showcasing a robust mechanism that distinguishes it from other treatments.
In pre-clinical trials, DA-1726 displayed superior weight loss effects compared to established treatments like semaglutide and cotadutide, enhancing its profile as a leading candidate in weight management therapies. Moreover, in mouse models, DA-1726 yielded similar weight loss outcomes while permitting higher food intake, all while preserving lean body mass.
Phase 1 Trial Results
The results of a Phase 1 multiple ascending dose (MAD) trial underline DA-1726's potential to be classified as a best-in-class therapy for weight loss. Not only did it show promising outcomes in terms of glucose control, but it also demonstrated a notable reduction in waist circumference among participants.
MetaVia's Commitment to Innovation
MetaVia is not only dedicated to DA-1726 but is also actively engaged in the development of another promising therapeutic, Vanoglipel (DA-1241). This compound is aimed at tackling MASH by functioning as a G-protein-coupled receptor 119 (GPR119) agonist that encourages the release of critical gut peptides such as GLP-1, GIP, and PYY.
In pre-clinical studies, DA-1241 showed positive effects on liver health, including reductions in hepatic inflammation, lipid metabolism, and significant improvements in glucose control. The alignment of these two key projects reflects MetaVia's strategic focus on innovative solutions for managing obesity and metabolic disorders.
Calling for Awareness and Collaboration
As MetaVia prepares for these important presentations, the company invites discussions around potential collaborations and partnerships that could drive forward the advancement of treatments for obesity and metabolic diseases. For more information about these therapeutic innovations and the latest data, interested parties are encouraged to stay connected with MetaVia.
Frequently Asked Questions
What is DA-1726?
DA-1726 is a novel dual agonist targeting GLP1R and GCGR approved for further clinical studies aimed at treating obesity and metabolic disorders.
When will the presentations take place?
The poster presentations are scheduled for November 4, 2025, during ObesityWeek 2025.
Who are the presenting authors for the posters?
The presentations will be made by Chris Fang, M.D., and Tae-Hyoung Kim, M.S.
What makes DA-1726 different from other obesity treatments?
DA-1726 acts as a dual agonist, enabling weight loss through appetite suppression while increasing energy expenditure, setting it apart from many current options.
How can I learn more about MetaVia’s clinical research?
For the latest updates and detailed information on MetaVia’s projects, visit their official website.
